Amgen Joins Medtronic to Fight Nerve Disease
- Share via
Amgen Inc., the Thousand Oaks biotechnology giant, has signed a joint-research agreement with Medtronic Inc. of Minneapolis in an effort to treat such nerve disorders as Lou Gehrig’s disease.
The partners hope to produce an implantable pump that will deliver a drug being developed by Amgen and Regeneron Pharmaceuticals of Tarrytown, N.Y. The drug, called brain-derived neurotrophic factor, would be delivered directly to a patient’s central nervous system.
Medtronic is a medical device manufacturer whose products include heart pacemakers. Financial terms of the project were not disclosed.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
